Psilocybin and D-Serine

Phase 1Small molecule

HHadassah Medical Organization

Psilocybin and D-Serine is one of 5 small molecule programs targeting Psilocybin. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PsilocybinRecruiting

PsilocybinPhase 1

Recruiting

Competition

Competitive Landscape

5 competitors in Psilocybin

#DrugCompanyPhaseTrials

Psilocybin

COMPASS Pathways

Phase 3

38 2

Risperdal

WWim Janssens

Phase 1

1 3

Versed

CConrado Roberto Hoffmann Filho

Phase 1

1 4

Psilocybin Therapy

UUniversity of California, San Francisco

Phase 2

1 5

Psilocybin and D-Serine

HHadassah Medical Organization

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Psilocybin

NCT07079930

Clinical

Trials by Indication[1]

Psilocybin1 trial

Safety and Psychological Effects of Psilocybin and D-Serine Formulation in Healthy Volunteers

Recruiting·HHadassah Medical Organization·Phase 1·NCT07079930·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Psilocybin and D-Serine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Psilocybin and D-Serine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Psilocybin and D-Serine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hadassah Medical Organization company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: HHadassah Medical Organization

Psilocybin and D-Serine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Psilocybin1 trial

References

Drug Info

Quick Facts

Related News